Filter documents Clear search

pdf icon

FSRH CEU Statement on Nexplanon® Insertion Site 15 January 2020

File size: 327kb | Date: 15 January 2020 | Clinical Statements - PDF

This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD (manufacturer of Nexplanon®) to healthcare professionals in the UK about updated guidance regarding the recommended Nexplanon® insertion site.

pdf icon

FSRH CEU Statement Response to Edelman 2022 (August 2022)

File size: 402kb | Date: 4 August 2022 | Clinical Statements - PDF

A new study (Edelman 2022) adds to the evidence around use of LNG-EC by those with higher weight/BMI but does not give a clear enough picture to inform any change in guidance.

pdf icon

FSRH CEU Statement: Response to Endler 2022 (July 2022)

File size: 357kb | Date: 6 July 2022 | Clinical Statements - PDF

A recently-published literature review considers the evidence around mechanism of action of levonorgestrel oral emergency contraception (LNG-EC). The findings support current FSRH guidance on emergency contraception, and are reassuring for those with ethical concerns about post-ovulation effects.

pdf icon

FSRH CEU Statement: Response to Heikinheimo 2022 (June 2022)

File size: 505kb | Date: 22 June 2022 | Clinical Statements - PDF

This FSRH Statement responses to a recently published cohort study, which used information from Finnish databases, assessed incidence of confirmed venous thromboembolic (VTE) events in 2018/19 amongst the roughly 300,000 Finnish people aged 15-49 who were using hormonal contraception (HC) in 2017 (identified from the prescribing database) and age-matched controls who were not using hormonal contraception.

pdf icon

FSRH CEU Resource: New one-handed, reloadable 52mg levonorgestrel-releasing intrauterine system

File size: 372kb | Date: 10 November 2021 | Clinical Statements - PDF

Benilexa® (Gedeon Richter) - a 52mg levonorgestrel-releasing intrauterine system (LNG-IUS) with a reloadable one-handed insertion device - is now available in the UK. Benilexa is licensed for 6 years of use for contraception. It is not licensed for endometrial protection as part of HRT. This FSRH CEU Resource provides a table which compares the product characteristics of LNG-IUS devices currently available in the UK, Benilexa®, Levosert®, Mirena®, Kyleena® and Jaydess®.

pdf icon

Telemedical abortion care: Safeguarding Young People

File size: 545kb | Date: 9 July 2021 | Clinical Statements - PDF

Statement from the Royal College of Obstetricians & Gynaecologists (RCOG), the Faculty of Sexual and Reproductive Healthcare and the British Society of Abortion Care Providers (BSACP) regarding the advent of telemedical abortion care and the safeguarding of young people.